PARIS (FRANCE) – AstraZeneca France president Olivier Nataf on Friday that the situation regarding the COVID-19 vaccine being developed by AstraZeneca is generally encouraging. It was added that new trial will be needed.
Nataf told RTL radio, “We are in a context that is encouraging.”
However, AstraZeneca has been facing questions about its success rate, which some experts say could hamper its chances of gaining speedy approval from US and EU regulatory bodies.